| 词条 | OncoMed | ||||||||||||||||||||||||||||||||
| 释义 |
| name = OncoMed Pharmaceuticals, Inc. | type = Public | industry = Pharmaceutical | foundation = University of Michigan {{start date and age|2004|08}} | founders = {{ubl|Michael Clarke|Max Wicha}} | key_people = {{ubl|Paul Hastings (CEO)|John Lewicki (R&D chief)|Chuck Alaimo (Operations director)}} | location_city = Redwood City, California | location_country = United States | num_employees = {{ubl|83 (2013)|47 (2007)}} | assets = {{currency|207.6 million|US}} [1] | assets_year = 2016 | traded_as = {{NASDAQ|OMED}} | revenue = {{currency|24.7 million|US}} (2012) | footnotes = [2][3][4][5] }}OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California.[2] The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha.[2][4] {{As of|2013}}, the company had 83 employees.[3] OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells".[3] The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company.[4] OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.[3][4] HistoryOncomed was incorporated in Delaware in 2004. In 2007, Oncomed consolidated its operations located in Mountain View and Palo Alto, California onto the single headquarters campus at Seaport Centre in Redwood City.[2] One of the buildings on the new campus was the former home of NeXT.[2] In 2012, OncoMed sponsored the USAN nonproprietary name vantictumab for a human IgG2 anti-Frizzled antibody, an anti-cancer therapeutic.[16] In the same year, the company sponsored the USAN name demcizumab for a human IgG2 anti-DLL4 antibody, also an anti-cancer therapeutic.[17] In 2014, OncoMed entered into an anti-cancer stem cell therapeutic development agreement with Celgene encompassing demcizumab and five other biologics from OncoMed's pipeline.[18][19] {{As of|2013}}, co-founder Max Wicha was the director of the University of Michigan Comprehensive Cancer Center and remained a consultant to OncoMed, while co-founder Michael Clarke had taken up a position at Stanford University.[4]CompetitorsIn 2013, OncoMed had at least two direct competitors, both public American companies: Stemline Therapeutics and Verastem.[3] By 2014, the list of firms pursuing therapies targeting cancer stem cells had grown to include Boston Biomedical (a subsidiary of Dainippon Sumitomo Pharma), GlaxoSmithKline, Astellas Pharma, Sanofi (the American subsidiary) and Pfizer; however, Stemline and Verastem remain the only two competitors solely focused on cancer stem cells.[18] One analyst holds that OncoMed is the best positioned of the three companies focused on the cancer stem cell area.[18] Pipeline
Demcizumab, OMP-305B83, and OMP-131R10 are being developed in collaboration with Celgene. Tarextumab and brontictuzumab are being developed in collaboration with GlaxoSmithKline Vantictumab and ipafricept are being developed in collaboration with Bayer.[2] Corporate governance{{As of|2013}}, OncoMed's chief executive officer (CEO) was Paul Hastings,[3] who took the post in 2006.[34] {{As of|2007}}, the company's head of R&D was John Lewicki, and the director of operations was Chuck Alaimo.[2]Paul HastingsWhile serving as OncoMed's CEO, Hastings was also a member of the board of directors for the California Healthcare Institute and the Bay Area Biosciences Association, as well as chairing the board of the Biotechnology Industry Organization.[34] Hastings education includes a bachelor's degree in pharmacy from the University of Rhode Island.[34] References1. ^http://investor.shareholder.com/oncomed/secfiling.cfm?filingID=1564590-16-26741&CIK=1302573 2. ^http://www.oncomed.com/Pipeline.html 3. ^1 2 3 {{cite web | title=Paul J. Hastings | publisher=California Healthcare Institute | website=Leadership | url=http://www.chi.org/about/leadership/hastings.aspx | deadurl=yes | archivedate=2 Oct 2011 | archiveurl=https://web.archive.org/web/20111002104016/http://www.chi.org/about/leadership/hastings.aspx }} 4. ^1 2 3 4 5 6 {{cite news | author=De, Kanak Kanti | title=Is It Time To Consider OncoMed Pharmaceuticals Again? | date=14 Oct 2014 | work=Seeking Alpha | url=http://seekingalpha.com/article/2560445-is-it-time-to-consider-oncomed-pharmaceuticals-again | deadurl=no }} 5. ^1 {{cite web | title=Statement on a nonproprietary name adopted by the USAN Council | url=https://download.ama-assn.org/resources/doc/usan/x-pub/demcizumab.pdf?cb=1417490455&retrieve=yes | format=PDF | accessdate=1 Dec 2014 | deadurl=no | id=N12/07 | publisher=AMA }}{{registration required}} 6. ^1 {{cite news | title=OncoMed, Celgene in $3.3B+ Cancer Stem Cell Collaboration | author=Staff | date=January 1, 2014 | page=8 | work=Gen. Eng. Biotechnol. News | department=Industry Watch }} 7. ^1 2 {{cite news | agency=Reuters | author=Grover, Natalie | title=OncoMed halts enrollment in trials of two cancer drugs | date=13 Jun 2014 | url=https://www.reuters.com/article/2014/06/13/us-oncomed-study-idUSKBN0EO1B920140613 | deadurl=no }} 8. ^1 2 3 4 5 6 {{cite news | author=Leuty, Ron | title=The NeXT big thing: OncoMed finds a home | date=28 Oct 2007 | work=San Francisco Business Times | url=http://www.bizjournals.com/sanfrancisco/stories/2007/10/29/focus6.html?page=all | deadurl=no }} 9. ^1 2 {{cite news | author=Leuty, Ron | title=OncoMed targets 4 million shares in IPO | date=5 Jul 2013 | work=San Francisco Business Times | url=http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/07/oncomed-ipo-cancer-stem-cells-bayer-gsk.html | deadurl=no }} 10. ^1 {{cite press release | publisher=OncoMed | title=OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 (Anti-Notch2/3) in Small Cell Lung Cancer (SCLC) and Amends Phase1b/2 Pancreatic Cancer Trial | url=http://files.shareholder.com/downloads/AMDA-20K1SK/3646503054x0x675682/d0fd1bf7-5edd-4aa2-8dca-e525ac9867a2/675682.pdf | deadurl=no | date=14 May 2013 | format=PDF }} 11. ^1 2 3 4 5 6 {{cite news | author=Timmerman, Luke | work=Xconomy | location=United States | date=18 Jun 2013 | title=OncoMed Pharmaceuticals Soars in IPO Debut | url=http://www.xconomy.com/san-francisco/2013/07/18/oncomed-pharmaceuticals-soars-in-ipo-debut/ | deadurl=no }} 12. ^1 2 3 4 5 {{cite press release | publisher=University of Michigan Health System | title=U-M start-up OncoMed has initial public offering | date=22 Jul 2013 | url=http://www.uofmhealth.org/news/archive/201307/u-m-start-oncomed-has-initial-public-offering | deadurl=no }} 13. ^1 {{cite web | title=Statement on a nonproprietary name adopted by the USAN Council | url=https://download.ama-assn.org/resources/doc/usan/x-pub/vantictumab.pdf?cb=1417489538&retrieve=yes | format=PDF | deadurl=no | date=28 Nov 2012 | id=N12/155 | publisher=AMA }}{{registration required}}
}} External links
| name = OncoMed | symbol = OMED | sec_cik = 1302573 | yahoo = OMED | google = OMED | bloomberg = OMED:US }}{{Authority control}} 5 : 2004 establishments in California|Pharmaceutical companies established in 2004|American companies established in 2004|Companies based in Redwood City, California|Companies listed on NASDAQ |
||||||||||||||||||||||||||||||||
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。